WNT3A and prostate carcinoma: Additionally, the treatment of LNCaP human prostate cancer cells with conditioned medium containing the growth factor Wnt3a significantly enhanced cell growth in the absence of androgens, demonstrating that the Wnt pathway may represent a novel mechanism contributing to prostate cancer progression [24].